IL105521A0 - The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds - Google Patents

The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds

Info

Publication number
IL105521A0
IL105521A0 IL105521A IL10552193A IL105521A0 IL 105521 A0 IL105521 A0 IL 105521A0 IL 105521 A IL105521 A IL 105521A IL 10552193 A IL10552193 A IL 10552193A IL 105521 A0 IL105521 A0 IL 105521A0
Authority
IL
Israel
Prior art keywords
inflammations
wounds
inhibitors
treatment
plasminogen activators
Prior art date
Application number
IL105521A
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IL105521A0 publication Critical patent/IL105521A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL105521A 1992-04-30 1993-04-27 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds IL105521A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (en) 1992-04-30 1992-04-30 USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION

Publications (1)

Publication Number Publication Date
IL105521A0 true IL105521A0 (en) 1993-08-18

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105521A IL105521A0 (en) 1992-04-30 1993-04-27 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds

Country Status (16)

Country Link
EP (1) EP0567816A1 (en)
JP (1) JPH069425A (en)
KR (1) KR930021179A (en)
CN (1) CN1080873A (en)
AU (1) AU3822993A (en)
CA (1) CA2095207A1 (en)
CZ (1) CZ76893A3 (en)
DE (1) DE4214215A1 (en)
HU (1) HUT65755A (en)
IL (1) IL105521A0 (en)
MX (1) MX9302519A (en)
NO (1) NO931561L (en)
PL (1) PL298748A1 (en)
SK (1) SK41593A3 (en)
UY (1) UY23572A1 (en)
ZA (1) ZA933023B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DE69434048T2 (en) * 1993-07-19 2005-10-06 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogenic agents and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
JP2002526382A (en) * 1998-04-01 2002-08-20 バイオテック・オーストラリア・ピーティーワイ・リミテッド Use of protease inhibitors to treat skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
WO2000066139A2 (en) * 1999-04-29 2000-11-09 Ista Pharmaceuticals, Inc. Biochemical methods that eliminate corneal scars, opacification and haze
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (en) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション Client server system, object pooling method, and storage medium
PT1223971E (en) 1999-10-27 2005-10-31 Alexandra Lucas COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF TRANSPLANT REJECTION
JP2001247458A (en) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd Therapeutic agent for diabetes comprising zinc tranexmate compound
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
KR100819895B1 (en) 2000-10-16 2008-04-07 코너 메드시스템즈 인코포레이티드 Expandable medical device for delivery of beneficial agent
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
BRPI0906167A2 (en) * 2008-01-21 2018-05-22 Dermadis S A Serine protease inhibitor use in the treatment of skin diseases.
TWI763960B (en) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 Method and medicine for preventing or treating osteoarthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
DK0458937T3 (en) * 1989-12-20 1998-02-23 Biotech Australia Pty Ltd Variants of PAI-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
HUT65755A (en) 1994-07-28
MX9302519A (en) 1993-10-01
NO931561L (en) 1993-11-01
AU3822993A (en) 1993-11-04
SK41593A3 (en) 1993-11-10
KR930021179A (en) 1993-11-22
ZA933023B (en) 1994-10-31
NO931561D0 (en) 1993-04-29
UY23572A1 (en) 1993-05-04
EP0567816A1 (en) 1993-11-03
DE4214215A1 (en) 1993-11-04
PL298748A1 (en) 1993-12-27
HU9301272D0 (en) 1993-07-28
CN1080873A (en) 1994-01-19
CZ76893A3 (en) 1994-01-19
JPH069425A (en) 1994-01-18
CA2095207A1 (en) 1993-10-31

Similar Documents

Publication Publication Date Title
IL105521A0 (en) The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
AU2956492A (en) Antibacterial agent and treatment of article therewith
AU5590596A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
EP0746202A4 (en) Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty
EP0581581A3 (en) Bioadhesive treatment compositions and methods of use
GB9222292D0 (en) Treatment of rubber articles
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
AP9300555A0 (en) Therapeutic agent and its use
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
AU2843397A (en) Agent for prophylaxis and treatment of disturbance of visual function
GB2294637B (en) Therapeutic compositions and methods of use
AU4319393A (en) Use of indolocarbazols in aids treatment
NZ255753A (en) Use of substituted azaspiranes for psoriasis treatment
AU612562B2 (en) A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis
EP0502470A3 (en) Compounds for the treatment of inflammation and allergy
GB9216360D0 (en) Treatment of blood
AU5532094A (en) Therapeutic agents for the treatment of cachexia
GB9317989D0 (en) Treatment of laminitis
AU3286893A (en) Therapeutic device and method of treatment
ZA929143B (en) Agents for use in the prophylaxis and therapy of fungal infections.
GB9000629D0 (en) Tissue plasminogen activator
GB9212535D0 (en) Treatment of boimass
IE872091L (en) Combination of tissue plasminogen activator and a¹prostaglandin